Oncology & Cancer

New drug combination passes safety test in pancreatic cancer

A new study has shown a novel peptide antagonist, given in combination with a PD-1 inhibitor, to be safe and well-tolerated in patients with advanced, refractory pancreatic and rectal cancer. The highest dose tested had a ...

page 1 from 3